To receive all of Acticor Biotech’s financial information in real time, send a request by email to [email protected]
Paris, France, February 2, 2022 – 6:00 p.m. CET – Acticor Biotech, a clinical-stage biotechnology company developing an innovative drug for the treatment of cardiovascular emergencies, today announces the results of the GARDEN trial, its clinical study in patients COVID-19 patients with Acute Respiratory Distress Syndrome (ARDS), evaluating glenzocimab (ACT017), a humanized monoclonal antibody fragment targeting platelet glycoprotein VI (GPVI).
GARDEN (NCT04659109) is a Phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled, parallel group study at a daily dose of 1000 mg of glenzocimab for three consecutive days, with the objective of evaluating the safety and the efficacy of glenzocimab.